Venetoclax-Dexamethasone Versus Pomalidomide-Dexamethasone in t(11;14)-Positive Relapsed/Refractory Multiple Myeloma: Primary Results of the Randomized, Phase III CANOVA Study.

Journal:

Journal of Clinical Oncology

Published:

2025-12-11

DOI:

10.1200/jco-25-00924

Affiliations:

26

Authors:

28

Go to article

Institutions	Authors	Share
AbbVie, United States of America (USA)	5.000000	0.18
Genentech, Inc., United States of America (USA)	3.000000	0.11
Institute of Hematology and Blood Diseases Hospital, CAMS & PUMC, China	1.000000	0.04
Pharmacyclics Switzerland, Switzerland	1.000000	0.04
Ankara University, Turkey	1.000000	0.04
Singapore General Hospital (SGH), Singapore	1.000000	0.04
AbbVie -UK, United Kingdom (UK)	1.000000	0.04
Arnie Charbonneau Cancer Institute, Canada	1.000000	0.04
University Hospital of Würzburg (UKW), JMU, Germany	1.000000	0.04
University College London Hospitals NHS Foundation Trust (UCLH), United Kingdom (UK)	1.000000	0.04
Japanese Red Cross Medical Center, Japan	1.000000	0.04
Nagoya City University, Japan	1.000000	0.04
Hadassah Medical Center, HUJI, Israel	1.000000	0.04
Mayo Clinic, United States of America (USA)	1.000000	0.04
Liverpool Hospital, Australia	1.000000	0.04
University Hospital Nantes (CHU de Nantes), France	1.000000	0.04
Cleveland Clinic Taussig Cancer Center, United States of America (USA)	1.000000	0.04
Ulsan University Hospital, UOU, South Korea	1.000000	0.04
Theageneio Hospital of Thessaloniki, Greece	1.000000	0.04
National and Kapodistrian University of Athens (UOA), Greece	0.500000	0.02
Korea University, South Korea	0.500000	0.02
A.O.U. Citta della Salute e della Scienza di Torino, Italy	0.500000	0.02
University of Turin (UNITO), Italy	0.500000	0.02
Institute of Molecular and Cell Biology of Cancer (IBMCC), Spain	0.333333	0.01
Institute of Biomedical Research of Salamanca (IBSAL), Spain	0.333333	0.01
Centro de Investigación Biomédica en Red de Cáncer (CIBERONC), Spain	0.333333	0.01

Interested in Oncology and Carcinogenesis?